Nkarta (NKTX) Stock Price, News & Analysis

Company Overview

Nkarta, Inc. is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies. Additional pipeline candidates include NKX101, targeting acute myeloid leukemia, and a series of discovery-stage assets directed against solid tumor antigens. By combining a renewable NK cell source with scalable manufacturing processes, Nkarta seeks to deliver standardized, “off-the-shelf” treatments that can be administered without the delays and logistical complexities associated with patient-derived cell therapies.

Founded by a team of immunotherapy and cell therapy experts, Nkarta is headquartered in South San Francisco, California. The company conducts its clinical trials across multiple sites in the United States and collaborates with academic institutions to advance its research. Nkarta’s leadership team is led by President and Chief Executive Officer James G. Joyce, Ph.D., who brings experience from prior senior roles in cell therapy development and commercialization.

As a Nasdaq-listed company (NKTX), Nkarta continues to focus on accelerating clinical development, optimizing manufacturing scale-up and establishing strategic partnerships to broaden access to its NK cell therapy platforms. Through ongoing research and clinical studies, the company aims to establish new standards in off-the-shelf cell-based immunotherapies for patients with high-unmet-need cancers.

Key Stats

• Today's Range: $2.64 to $2.86
• 50-Day Range: $2.00 to $3.49
• 52-Week Range: $1.63 to $3.65
• Volume: 729,448 shs
• Average Volume: 821,782 shs
• Market Capitalization: $188.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.33
• Consensus Rating: Moderate Buy

Nkarta Stock Analysis - MarketRank™

Nkarta scored higher than 68% of companies evaluated by MarketBeat, and ranked 215th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nkarta has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Nkarta has a consensus price target of $11.33, representing about 329.3% upside from its current price of $2.64.

Amount of Analyst Coverage

Nkarta has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nkarta are expected to grow in the coming year, from ($1.51) to ($1.44) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nkarta is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nkarta is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nkarta has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.07% of the float of Nkarta has been sold short.

Short Interest Ratio / Days to Cover

Nkarta has a short interest ratio ("days to cover") of 3.88, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nkarta has recently decreased by 2.47%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nkarta does not currently pay a dividend.

Dividend Growth

Nkarta does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.61

News Sentiment

Nkarta has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Nkarta this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for NKTX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

8 people have added Nkarta to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nkarta insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.40% of the stock of Nkarta is held by insiders.

Percentage Held by Institutions

80.54% of the stock of Nkarta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 5/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NKTX
• CIK: 1787400
• Web: www.nkartatx.com
• Phone: 925-407-1049
• Fax: N/A
• Employees: 140
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Nkarta: $11.33
• High Price Target: $12.00
• Low Price Target: $11.00
• Potential Upside/Downside: +329.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$104.08 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -30.90%
• Return on Assets: -24.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.96
• Quick Ratio: 12.69

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.00 per share
• Price / Book: 0.66

Miscellaneous

• Outstanding Shares: 71,540,000
• Free Float: 65,303,000
• Market Cap: $188.87 million
• Optionable: Optionable
• Beta: 0.88